As CGM was introduced in 2020 for type 1 diabetes in South Korea and, as national insurance has covered (from November 2024) the cost of CGM in women with type 2 diabetes and gestational diabetes requiring insulin, further studies about glycemic control and pregnancy outcomes are needed. Here, INS is linked to type 1 diabetes mellitus.